Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow for the year ending March 31, 2024: USD 4.14 M

Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow is USD 4.14 M for the year ending March 31, 2024, a -80.71% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow for the year ending March 31, 2023 was USD 21.47 M, a -25.27% change year over year.
Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow for the year ending March 31, 2022 was USD 28.74 M, a -1.48% change year over year.
Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow for the year ending March 31, 2021 was USD 29.17 M, a -45.22% change year over year.
Fuso Pharmaceutical Industries,Ltd. Operating Cash Flow for the year ending March 31, 2020 was USD 53.25 M, a 187.85% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years